Cortactin, fascin and survivin expression associated with clinicopathological parameters in brain gliosarcoma

Chinese Journal of Physiology

Volumn 53, Issue 4, 2010, Pages 234-244

  Chen, Jia Hong ^a   Chen, Kuan Yu ^a   Ma, Hsin I ^a   Yu, Cheng Ping ^a   Nieh, Shin ^a   Lee, Herng Sheng ^a   Jin, Jong Shiaw ^a  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

Cortactin; Fascin; Gliosarcoma; Survivin

Indexed keywords

CORTACTIN; FASCIN; GLIAL FIBRILLARY ACIDIC PROTEIN; SURVIVIN; VIMENTIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CRANIOTOMY; CYTOPLASM; FEMALE; GLIOSARCOMA; HEADACHE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MALIGNANT TRANSFORMATION; PARESTHESIA; PARIETAL LOBE; PROTEIN EXPRESSION; SURVIVAL TIME; SYMPTOMATOLOGY; TUMOR CELL; TUMOR VOLUME; WEAKNESS;

EID: 78149431662     PISSN: 03044920     EISSN: 26660059     Source Type: Journal    
DOI: 10.4077/CJP.2010.AMK062     Document Type: Article

References (26)

1. Adams, J.C. Roles of fascin in cell adhesion and motility. Curr. Opin. Cell Biol. 16: 590-596, 2004.
2. Ambrosini, G., Adida, C. and Altieri, D.C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nature Med. 3: 917-921, 1997.
3. Burger, P.C. and Scheithauer, B.W. Glycosarcoma. In: Tumors of the Central Nervous System. Washington DC: Armed Forces Institute of Pathology, 1994, vol. 6, pp. 68-70.
4. Daly, R.J. Cortactin signaling and dynamic actin networks. Biochem. J. 382: 13-25, 2004.
5. Hofman, P., Butori, C., Havet, K., Hofman, V., Selva, E. and Guevara, N. Prognostic significance of cortactin levels in head and neck squamous cell carcinoma: comparison with epidermal growth factor receptor status. Br. J. Cancer 98: 956-964, 2008.
6. Jack, C.R. Jr, Bhansali, D.T., Chason, J.L., Boulos, R.S., Mehta, B.A. and Patel, S.C. Angiographic features of gliosarcoma. AJNR 8: 117-122, 1987.
7. Kaschten, B., Flandroy, P., Reznik, M., Hainaut, H. and Stevenaert, A. Radiation induced gliosarcoma: case report and review of the literature. J. Neurosurg. 83: 154-162, 1995.
8. Katsuyuki, S.A., Yoshiyuki, S.A., Kuniyuki, O.A., Shin-ei, N.A. Hiroyuki, K.A., Yoshihiko, S.A. et al. Nuclear survivin expression predicts poorer prognosis in glioblastoma. J. Neurooncol. 91: 353-358, 2009.
9. Lam, J.S., Belldegrun, A.S. and Figlin, R.A. Tissue array-based predictions of pathobiology, prognosis and response to treatment for renal cell carcinoma therapy. Clin. Cancer Res. 10: 6304s-6309s, 2004.
10. Li, F., Ambrosini, G., Chu, E.Y., Plescia, J., Tognin, S. and Marchisio, P.C. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396: 580-584, 1998.
11. Luo, M.L., Shen, X.M., Zhang, Y., Wei, F., Xu, X. and Cai, Y. Amplification and overexpression of CTTN (EMS1) contribute to the metastasis of esophageal squamous cell carcinoma by promoting cell migration and anoikis resistance. Cancer Res. 66: 11690-11699, 2006.
12. Lutterbach, J., Guttenberger, R. and Pagenstecher, A. Gliosarcoma: a clinical study. Radiotherapy Oncol. 61: 57-64, 2001.
13. Machuca, T.N., Prevedello, D.M., Pope, L.Z., Haratz, S.S., Araujo, J.C. and Torres, L.F. Gliosarcoma: Report of four cases with immunohistochemical findings. Arq. Neuro-Psiquiatr. 62: 608-612, 2004.
14. Meis, J.M., Martz, K.L. and Nelson, J.S. Mixed glioblastoma multiforme and sarcoma: a clinicopathologic study of 26 Radiation Therapy Oncology Group cases. Cancer 67: 2342-2349, 1991.
15. Morantz, R.A., Feigin, I. and Ransohoff, J. Clinical and pathological study of 24 cases of gliosarcoma. J. Neurosurg. 45: 398-408, 1976.
16. Ohgaki, H., Biernat, W., Reis, R., Hegi, M. and Kleihues, P. Gliosarcoma. In: Pathology and Genetics of Tumors of the Nervous System. Lyon: IARC Press, 2000, vol. 8. pp. 42-44.
17. Perry, J.R., Ang, L.C., Bilbao, J.M. and Muller, P.J. Clinicopathologic features of primary and post-radiation cerebral gliosarcoma. Cancer 75: 2910-2918, 1995.
18. Reis, R.M., Konu-Lebleblicioglu, D., Lopes, J.M., Kleihues, P. and Ohgaki, H. Genetic profile of gliosarcomas. Am. J. Pathol. 156: 425-432, 2000.
19. Tsai, W.C., Jin, J.S., Chang, W.K., Chan, D.C., Yeh, M.K. and Cherng, S.C. Association of cortactin and fascin-1 expression in gastric adenocarcinoma: correlation with clinicopathological parameters. J. Histochem. Cytochem. 55: 955-962, 2007.
20. van Rossum, A.G., Gibcus, J., van der Wal, J. and Schuuring, E. Cortactin overexpression results in sustained epidermal growth factor receptor signaling by preventing ligand-induced receptor degradation in human carcinoma cells. Breast Cancer Res. 7: 235-237, 2005.
21. Williams, M.E., Gaffey, M.J., Weiss, L.M., Wilczynski, S.P., Schuuring, E. and Levine, P.A. Chromosome 11Q13 amplification in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 119: 1238-1243, 1993.
22. Witwer, B.P., Salamat, M.S. and Resnick, D.K. Gliosarcoma metastatic to the cervical spinal cord: case report and review of the literature. Surg. Neurol. 54: 373-378, 2000.
23. Wu, H. and Parsons, J.T. Cortactin, an 80/85-kilodalton pp60src substrate, is a filamentous actin-binding protein enriched in the cell cortex. J. Cell Biol. 120: 1417-1426, 1993.
24. Xie, J.J., Xu, L.Y., Zhang, H.H., Cai, W.J., Mai, R.Q. and Xie, Y.M. Role of fascin in the proliferation and invasiveness of esophageal carcinoma cells. Biochem. Biophys. Res. Commun. 337: 355-362, 2005.
25. Yamashiro, S. Yamakita, Y. Ono, S. and Matsumura, F. Fascin, an actin-bundling protein, induces membrane protrusions and increases cell motility of epithelial cells. Mol. Biol. Cell 9: 993-1006, 1998.
26. Yamazaki, D., Kurisu, S. and Takenawa, T. Regulation of cancer cell motility through actin reorganization. Cancer Sci. 96: 379-386, 2005.